Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 87

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
3 340
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 340 trials in Villejuif

Open in trial search

Analgesic therapy

Recruiting

Study on Pain Relief for Limb Injuries in Children: Comparing Intranasal Fentanyl, Intranasal Ketamine, and Oral Morphine in Patients Aged 2-17 Years

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fentanyl Citrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Hepatocellular carcinoma

Recruiting

Study on Atezolizumab, Bevacizumab, and EXL01 for Patients with Liver Cancer Not Responding to First-Line Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre De Lutte Contre Le Cancer Eugene Marquis

Acute respiratory distress syndrome

Recruiting

Study on Dornase Alfa and Placebo to Reduce ARDS in Ventilated Trauma Patients in ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Liver transplant

Recruiting

Study on the Effects of Tacrolimus and Mycophenolate Mofetil in Patients After Liver Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Centre Hospitalier Et Universitaire De Limoges

Breast cancer+2

Recruiting

Study on Pembrolizumab and Paclitaxel for Early Triple-Negative Breast Cancer in Patients with High Tumor-Infiltrating Lymphocytes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Institut Gustave Roussy

Dementia Alzheimer's type

Recruiting

Long-Term Safety Study of ACP-204 for Adults with Alzheimer's Disease Psychosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Acadia Pharmaceuticals Inc.

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment: Evaluating the Effectiveness of Topotecan, Vincristine Sulfate, and Etoposide in Patients Eligible for Conservative Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Metastases to central nervous system

Recruiting

Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Institut De Cancerologie De L Ouest

Hormone-refractory prostate cancer

Recruiting

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Rheumatoid arthritis

Recruiting

Study on Reducing JAK Inhibitor Doses in Patients with Low Disease Activity in Rheumatoid Arthritis Using Tofacitinib and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Prostate cancer metastatic

Recruiting

Study of talazoparib and enzalutamide combination treatment for patients with metastatic prostate cancer who previously received abiraterone

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Fundacion Oncosur

Squamous cell carcinoma of head and neck

Recruiting

Study of Amivantamab, Pembrolizumab, and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.